After its drug Palifosfamide failed to show efficacy in a phase 3 sarcoma trial, shares of Ziopharm Oncology (ZIOP +4.06%) fell through the floor, dropping by more than 66%. Do shareholders have any hope of a recovery? In this video, Motley Fool health-care analyst David Williamson takes us through what the cash situation looks like at Ziopharm, where the company will be shifting its focus next, and what, if any, hope remains.
Is Anything Left for Ziopharm Investors?
By Dave Williamson – Mar 26, 2013 at 7:37PM
NASDAQ: TCRT
Alaunos Therapeutics
Market Cap
$6.0M
Today's Change
(4.06%) $0.11
Current Price
$2.82
Price as of October 24, 2025 at 4:00 PM ET
Is there any hope for Ziopharm after this utter collapse?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid